董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Catherine D. Strader | 女 | Independent Director | 66 | 12.89万美元 | 未持股 | 2020-04-28 |
| Ron Cohen | 男 | President, Chief Executive Officer, Director | 64 | 203.96万美元 | 未持股 | 2020-04-28 |
| Barry Greene | 男 | Independent Director | 56 | 13.19万美元 | 未持股 | 2020-04-28 |
| John P. Kelley | 男 | Independent Director | 66 | 16.09万美元 | 未持股 | 2020-04-28 |
| Sandra Panem | 女 | Independent Director | 73 | 13.59万美元 | 未持股 | 2020-04-28 |
| Lorin J. Randall | 男 | Independent Director | 76 | 13.79万美元 | 未持股 | 2020-04-28 |
| Steven M. Rauscher | 男 | Independent Director | 66 | 13.19万美元 | 未持股 | 2020-04-28 |
| Peder K. Jensen | 男 | Independent Director | 65 | 20.50万美元 | 未持股 | 2020-04-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Burkhard Blank | 男 | Chief Medical Officer and Head of R&D | 65 | 120.26万美元 | 未持股 | 2020-04-28 |
| Ron Cohen | 男 | President, Chief Executive Officer, Director | 64 | 203.96万美元 | 未持股 | 2020-04-28 |
| David Lawrence | 男 | Chief, Business Operations and Principal Accounting Officer | 62 | 91.28万美元 | 未持股 | 2020-04-28 |
| Lauren M. Sabella | 女 | Chief Commercial Officer | 59 | 92.20万美元 | 未持股 | 2020-04-28 |
董事简历
中英对照 | 中文 | 英文- Catherine D. Strader
-
CatherineD.Strader自2017年2月以来一直是我们的董事会成员。Strader博士是Synergy Partners研发解决方案公司（Synergy Partners R&D Solutions）的合伙人，该公司是由Strader博士于2014年共同创立的咨询网络，为生物技术公司提供研究与开发战略方面的建议。在共同创立Synergy Partners之前，Strader博士曾在Merck Research Laboratories工作，2009年至2011年担任Vice President和网站负责人，2007年至2009年担任外部基础研究Vice President。在此之前，在先灵葆雅公司于2009年被默克公司收购之前，Strader博士曾在Schering-PloughCorporation公司担任领导职务，包括2007年的高级副总裁，科技公司和2006年至2007年的首席科学官。在此之前，Strader博士从2002年到2007年担任Schering-Plough Research Institute的发现研究执行Vice President，从1995年到2001年担任Vice President、中枢神经系统、心血管和基因组学研究执行副总裁。Strader博士在她的职业生涯中通过药物发现和开发指导了50多种化合物。Strader博士在弗吉尼亚大学（University of Virginia）获得化学学士学位，在加州理工学院（California Institute of Technology）获得化学博士学位，随后在杜克大学（Duke University）获得霍华德休斯（Howard Hughes）博士后奖学金。
Catherine D. Strader has been a member of our Board of Directors since February 2017. Dr. Strader is a partner at Synergy Partners R&D Solutions, a consultancy network co-founded by Dr. Strader in 2014 which advises biotechnology companies on research and development strategies. Prior to co-founding Synergy Partners, Dr. Strader worked for Merck Research Laboratories, as Vice President and Site Head from 2009 to 2011 and as Vice President, External Basic Research from 2007 to 2009. Prior to that, Dr. Strader held leadership positions at Schering-Plough Corporation before Schering-Plough was acquired by Merck in 2009 including Senior Vice President, Science and Technology in 2007 and Chief Scientific Officer from 2006 to 2007. Prior to that, Dr. Strader was Executive Vice President, Discovery Research from 2002 to 2007 and Vice President, CNS, Cardiovascular and Genomics Research from 1995 to 2001 at Schering-Plough Research Institute. Dr. Strader has guided more than 50 compounds through drug discovery and development during her career. Dr. Strader received a B.S. in Chemistry from the University of Virginia and a Ph.D. in Chemistry from the California Institute of Technology, followed by a Howard Hughes postdoctoral fellowship at Duke University. - CatherineD.Strader自2017年2月以来一直是我们的董事会成员。Strader博士是Synergy Partners研发解决方案公司（Synergy Partners R&D Solutions）的合伙人，该公司是由Strader博士于2014年共同创立的咨询网络，为生物技术公司提供研究与开发战略方面的建议。在共同创立Synergy Partners之前，Strader博士曾在Merck Research Laboratories工作，2009年至2011年担任Vice President和网站负责人，2007年至2009年担任外部基础研究Vice President。在此之前，在先灵葆雅公司于2009年被默克公司收购之前，Strader博士曾在Schering-PloughCorporation公司担任领导职务，包括2007年的高级副总裁，科技公司和2006年至2007年的首席科学官。在此之前，Strader博士从2002年到2007年担任Schering-Plough Research Institute的发现研究执行Vice President，从1995年到2001年担任Vice President、中枢神经系统、心血管和基因组学研究执行副总裁。Strader博士在她的职业生涯中通过药物发现和开发指导了50多种化合物。Strader博士在弗吉尼亚大学（University of Virginia）获得化学学士学位，在加州理工学院（California Institute of Technology）获得化学博士学位，随后在杜克大学（Duke University）获得霍华德休斯（Howard Hughes）博士后奖学金。
- Catherine D. Strader has been a member of our Board of Directors since February 2017. Dr. Strader is a partner at Synergy Partners R&D Solutions, a consultancy network co-founded by Dr. Strader in 2014 which advises biotechnology companies on research and development strategies. Prior to co-founding Synergy Partners, Dr. Strader worked for Merck Research Laboratories, as Vice President and Site Head from 2009 to 2011 and as Vice President, External Basic Research from 2007 to 2009. Prior to that, Dr. Strader held leadership positions at Schering-Plough Corporation before Schering-Plough was acquired by Merck in 2009 including Senior Vice President, Science and Technology in 2007 and Chief Scientific Officer from 2006 to 2007. Prior to that, Dr. Strader was Executive Vice President, Discovery Research from 2002 to 2007 and Vice President, CNS, Cardiovascular and Genomics Research from 1995 to 2001 at Schering-Plough Research Institute. Dr. Strader has guided more than 50 compounds through drug discovery and development during her career. Dr. Strader received a B.S. in Chemistry from the University of Virginia and a Ph.D. in Chemistry from the California Institute of Technology, followed by a Howard Hughes postdoctoral fellowship at Duke University.
- Ron Cohen
-
Ron Cohen，医学博士，担任本公司总裁、首席执行官兼创始人。他曾参与Advanced Tissue Sciences Inc的创办，而该公司是一家生物技术公司，从事人体器官组织的培植和移植。他在普林斯顿大学获得心理学文学士学位，在哥伦比亚大学获得内外科医学博士学位。他在弗吉尼亚大学医学中心完成内科专业的实习，并获得认证。他目前担任 Dyax Corp的董事会成员。他曾担任纽约生物技术协会的董事兼董事会主席。他目前是生物技术工业组织（BIO）的执行委员会成员，并任其卫生科副科长。他还是哥伦比亚长老会医疗科学顾问委员会的成员，并荣获哥伦比亚大学卓越校友奖。2010年，他被任命为NeuroInvestment（现为NeuroPerspective）的年度执行总裁，且于2009年被PharmaVoice杂志评为生物医药产业百佳卓越人士。他是纽约大都会地区的安永企业家奖的获得者，且被列入全国脊髓损伤协会主办的“脊髓损伤大厅名人堂”。2010年，他被纽约生物技术协会评为NYBA“The Cure Starts Here”的年度商业领袖。
Ron Cohen has served as Dyax Corp. President and Chief Executive Officer since he founded the Company in 1995. Dr. Cohen previously was a principal in the startup of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen currently serves on the board of directors of VBL Therapeutics. In addition, within the last five years, he previously served on the board of directors of Dyax Corp. Dr. Cohen previously served as Chair of the board of the Biotechnology Innovation Organization BIO, as Chair of the Emerging Companies Section of the BIO board, and as a Director and Chairman of New York Biotechnology Association (NYBA). He also previously served as a member of the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University's Alumni Medal for Distinguished Service. In 2010 Dr. Cohen was named NeuroInvestment's (now called NeuroPerspective) CEO of the Year and in 2009 he was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. Dr. Cohen is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and is an inductee into the National Spinal Cord Injury Association's "Spinal Cord Injury Hall of Fame." In 2010 Dr. Cohen was recognized by NYBA as its "The Cure Starts Here" Business Leader of the Year and was named by MM&M and PR Week as one of the top 50 health influencers of 2017. - Ron Cohen，医学博士，担任本公司总裁、首席执行官兼创始人。他曾参与Advanced Tissue Sciences Inc的创办，而该公司是一家生物技术公司，从事人体器官组织的培植和移植。他在普林斯顿大学获得心理学文学士学位，在哥伦比亚大学获得内外科医学博士学位。他在弗吉尼亚大学医学中心完成内科专业的实习，并获得认证。他目前担任 Dyax Corp的董事会成员。他曾担任纽约生物技术协会的董事兼董事会主席。他目前是生物技术工业组织（BIO）的执行委员会成员，并任其卫生科副科长。他还是哥伦比亚长老会医疗科学顾问委员会的成员，并荣获哥伦比亚大学卓越校友奖。2010年，他被任命为NeuroInvestment（现为NeuroPerspective）的年度执行总裁，且于2009年被PharmaVoice杂志评为生物医药产业百佳卓越人士。他是纽约大都会地区的安永企业家奖的获得者，且被列入全国脊髓损伤协会主办的“脊髓损伤大厅名人堂”。2010年，他被纽约生物技术协会评为NYBA“The Cure Starts Here”的年度商业领袖。
- Ron Cohen has served as Dyax Corp. President and Chief Executive Officer since he founded the Company in 1995. Dr. Cohen previously was a principal in the startup of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen currently serves on the board of directors of VBL Therapeutics. In addition, within the last five years, he previously served on the board of directors of Dyax Corp. Dr. Cohen previously served as Chair of the board of the Biotechnology Innovation Organization BIO, as Chair of the Emerging Companies Section of the BIO board, and as a Director and Chairman of New York Biotechnology Association (NYBA). He also previously served as a member of the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University's Alumni Medal for Distinguished Service. In 2010 Dr. Cohen was named NeuroInvestment's (now called NeuroPerspective) CEO of the Year and in 2009 he was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. Dr. Cohen is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and is an inductee into the National Spinal Cord Injury Association's "Spinal Cord Injury Hall of Fame." In 2010 Dr. Cohen was recognized by NYBA as its "The Cure Starts Here" Business Leader of the Year and was named by MM&M and PR Week as one of the top 50 health influencers of 2017.
- Barry Greene
-
Barry Greene，自2007年1月起成为本公司董事会成员。他目前担任Alnylam Pharmaceuticals Inc的总裁兼首席营运官。他于2003年9月进入 Alnylam，当时已有15年多的医疗行业从业和咨询经验。在进入Alnylam之前，他曾在Millennium Pharmaceuticals Inc担任肿瘤科总经理，领导公司的全球策略和肿瘤业务的开展，包括战略业务方向、执行力以及2003年年中VELCADE bortezomib的成功审批。在2001年进入 Millennium之前，他在Mediconsult.com担任执行副总裁间首席商务官。而更早前，他曾在AstraZeneca（原AstraMerck）担任市场部和客户服务部副总裁；曾担任战略整合部副总裁，负责AstraZeneca North American的并购；担任Andersen Consulting的合伙人，负责药/生物技术营销和销售活动。他曾担任 Regulus Therapeutics LLC 和Intercept Pharmaceuticals Inc的董事会成员。他在匹兹堡大学获得工业工程专业理学士学位，并是杜克大学富卡商学院的高级进修生。
Barry Greene has served on our board of directors since October 2020. Mr. Greene has served as the Chief Executive Officer of Sage Therapeutics Nasdaq: SAGE since December 2020. Mr. Greene has served on the boards of directors of Acorda Therapeutics (Nasdaq: ACOR) since 2008 and Karyopharm (Nasdaq: KPTI) since 2012. Mr. Greene has more than 30 years of experience in the healthcare, pharmaceutical and biotechnology industries, including his most recent role as President of Alnylam (Nasdaq: ALNY) from October 2003 to September 2020. Prior to Alnylam, Mr. Greene served as General Manager of Oncology at Millennium (Nasdaq: MLNM) from 2001 to 2003 where he led the company,s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful approval and launch of Velcade (bortezomib) in mid-2003. Prior to joining Millennium, Mr. Greene served as Executive Vice President and Chief Business Officer of Mediconsult from 1999 to 2000. Earlier in his career, Mr. Greene held various roles with AstraZeneca (Lon: AZN) from 1997 to 1999 and was a partner with Andersen Consulting (now Accenture (NYSE: CAN)) from 1986 to 1997. Mr. Greene earned a BS in industrial engineering from the University of Pittsburgh and served as Senior Scholar at Duke University, Fuqua School of Business. - Barry Greene，自2007年1月起成为本公司董事会成员。他目前担任Alnylam Pharmaceuticals Inc的总裁兼首席营运官。他于2003年9月进入 Alnylam，当时已有15年多的医疗行业从业和咨询经验。在进入Alnylam之前，他曾在Millennium Pharmaceuticals Inc担任肿瘤科总经理，领导公司的全球策略和肿瘤业务的开展，包括战略业务方向、执行力以及2003年年中VELCADE bortezomib的成功审批。在2001年进入 Millennium之前，他在Mediconsult.com担任执行副总裁间首席商务官。而更早前，他曾在AstraZeneca（原AstraMerck）担任市场部和客户服务部副总裁；曾担任战略整合部副总裁，负责AstraZeneca North American的并购；担任Andersen Consulting的合伙人，负责药/生物技术营销和销售活动。他曾担任 Regulus Therapeutics LLC 和Intercept Pharmaceuticals Inc的董事会成员。他在匹兹堡大学获得工业工程专业理学士学位，并是杜克大学富卡商学院的高级进修生。
- Barry Greene has served on our board of directors since October 2020. Mr. Greene has served as the Chief Executive Officer of Sage Therapeutics Nasdaq: SAGE since December 2020. Mr. Greene has served on the boards of directors of Acorda Therapeutics (Nasdaq: ACOR) since 2008 and Karyopharm (Nasdaq: KPTI) since 2012. Mr. Greene has more than 30 years of experience in the healthcare, pharmaceutical and biotechnology industries, including his most recent role as President of Alnylam (Nasdaq: ALNY) from October 2003 to September 2020. Prior to Alnylam, Mr. Greene served as General Manager of Oncology at Millennium (Nasdaq: MLNM) from 2001 to 2003 where he led the company,s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful approval and launch of Velcade (bortezomib) in mid-2003. Prior to joining Millennium, Mr. Greene served as Executive Vice President and Chief Business Officer of Mediconsult from 1999 to 2000. Earlier in his career, Mr. Greene held various roles with AstraZeneca (Lon: AZN) from 1997 to 1999 and was a partner with Andersen Consulting (now Accenture (NYSE: CAN)) from 1986 to 1997. Mr. Greene earned a BS in industrial engineering from the University of Pittsburgh and served as Senior Scholar at Duke University, Fuqua School of Business.
- John P. Kelley
-
John P. Kelley，自2008年12月起担任本公司董事会成员。他自2013年11月至今担任Oxygen Biotherapeutics Inc的首席执行官，该公司专注于为重症监护市场开发产品。2011年至2013年，他曾任Phyxius Pharma Inc的总裁、行政总裁兼董事，该公司是一家成长型私营公司，由他于2011年联合创办而成，专注于急性护理设施产品的研发。当Oxygen Biotherapeutics于2013年被Phyxius Pharma收购时，他成为该公司的首席执行官。此前的2004年至2009年间，他曾担任Medicines Company（向全球提供急性护理的一家制药公司）的总裁兼首席营运官。2005至2009年间，他还担任Medicines Company的董事会成员。2000至2004年，他曾在Aventis（跨国制药公司）担任多项职务，包括全球营销和医疗业务高级副总裁，负责全球品牌管理。在 Aventis成立之前，他曾在Hoechst Marion Roussel Inc（专注于药品研发的生命科学公司）担任多项职务，包括：1998至1999年担任美国区商务总监兼副总裁，1995至1998年间担任市场部副总裁。在最近的5年里，他曾担任Medicines Company的董事会成员。他持有威尔克斯大学的文学士学位和罗克赫斯特大学的MBA学位。
John P. Kelley has been a member of our Board of Directors since December 2008 and was elected to serve as our non-executive Chair of the Board in November 2019. From November 2013 to April 2017 Mr. Kelley was Chief Executive Officer of Tenax Therapeutics, Inc. formerly named Oxygen Biotherapeutics, Inc., a company that focuses on developing products for the critical care market, where he also served as a member of the board of directors. From 2011 to 2013 Mr. Kelley was President, Chief Executive Officer, and a director of Phyxius Pharma, Inc., a privately-held development stage pharmaceutical company co-founded by Mr. Kelley in 2011 focused on developing products for use in acute care settings. Mr. Kelley became Chief Executive Officer of Tenax Therapeutics when it acquired Phyxius Pharma in 2013. Previously, Mr. Kelley was the President and Chief Operating Officer of The Medicines Company, a pharmaceutical company providing acute care hospital products worldwide, from 2004 to 2009. He also served on The Medicines Company’s board of directors from 2005 to 2009. From 2000 to 2004 Mr. Kelley held a series of positions at Aventis, a global pharmaceutical company, including Senior Vice President, Global Marketing and Medical, where he was accountable for worldwide brand management. Prior to the formation of Aventis, he held a series of positions at Hoechst Marion Roussel, Inc., a life sciences firm focused on pharmaceuticals, including, from 1998 to 1999 Vice President, Commercial Director, U.S. and, from 1995 to 1998 Vice President of Marketing. Mr. Kelley received a B.A. from Wilkes University and an M.B.A. from Rockhurst University. - John P. Kelley，自2008年12月起担任本公司董事会成员。他自2013年11月至今担任Oxygen Biotherapeutics Inc的首席执行官，该公司专注于为重症监护市场开发产品。2011年至2013年，他曾任Phyxius Pharma Inc的总裁、行政总裁兼董事，该公司是一家成长型私营公司，由他于2011年联合创办而成，专注于急性护理设施产品的研发。当Oxygen Biotherapeutics于2013年被Phyxius Pharma收购时，他成为该公司的首席执行官。此前的2004年至2009年间，他曾担任Medicines Company（向全球提供急性护理的一家制药公司）的总裁兼首席营运官。2005至2009年间，他还担任Medicines Company的董事会成员。2000至2004年，他曾在Aventis（跨国制药公司）担任多项职务，包括全球营销和医疗业务高级副总裁，负责全球品牌管理。在 Aventis成立之前，他曾在Hoechst Marion Roussel Inc（专注于药品研发的生命科学公司）担任多项职务，包括：1998至1999年担任美国区商务总监兼副总裁，1995至1998年间担任市场部副总裁。在最近的5年里，他曾担任Medicines Company的董事会成员。他持有威尔克斯大学的文学士学位和罗克赫斯特大学的MBA学位。
- John P. Kelley has been a member of our Board of Directors since December 2008 and was elected to serve as our non-executive Chair of the Board in November 2019. From November 2013 to April 2017 Mr. Kelley was Chief Executive Officer of Tenax Therapeutics, Inc. formerly named Oxygen Biotherapeutics, Inc., a company that focuses on developing products for the critical care market, where he also served as a member of the board of directors. From 2011 to 2013 Mr. Kelley was President, Chief Executive Officer, and a director of Phyxius Pharma, Inc., a privately-held development stage pharmaceutical company co-founded by Mr. Kelley in 2011 focused on developing products for use in acute care settings. Mr. Kelley became Chief Executive Officer of Tenax Therapeutics when it acquired Phyxius Pharma in 2013. Previously, Mr. Kelley was the President and Chief Operating Officer of The Medicines Company, a pharmaceutical company providing acute care hospital products worldwide, from 2004 to 2009. He also served on The Medicines Company’s board of directors from 2005 to 2009. From 2000 to 2004 Mr. Kelley held a series of positions at Aventis, a global pharmaceutical company, including Senior Vice President, Global Marketing and Medical, where he was accountable for worldwide brand management. Prior to the formation of Aventis, he held a series of positions at Hoechst Marion Roussel, Inc., a life sciences firm focused on pharmaceuticals, including, from 1998 to 1999 Vice President, Commercial Director, U.S. and, from 1995 to 1998 Vice President of Marketing. Mr. Kelley received a B.A. from Wilkes University and an M.B.A. from Rockhurst University.
- Sandra Panem
-
Sandra Panem，女，博士，自1998年以来担任本公司董事会成员。她自2000年至今担任Cross Atlantic Partners的合伙人。1994到1999年，她担任Vector Fund Management（当时为 Vector Securities International的附属资产管理机构）的总裁。在此之前，她曾担任Oppenheimer Global BioTech Fund（投资于公共和私营生物科技企业的共同基金）的总裁兼投资部经理。此前，她曾担任Salomon Brothers Venture Capital（专注于早期和晚期阶段的生命科学和科技投资的基金）的副总裁。她也是布鲁金斯学会经济研究处的一名科学与公共政策研究员，并在芝加哥大学担任病理学助理教授。她持有芝加哥大学的生物化学理学士学位和芝加哥大学的微生物学博士学位。她目前担任Labcyte Inc、GenomeQuest Inc和MDx Medical Inc的董事会成员。
Sandra Panem has been a member of our Board since 1998. She is currently a partner at Cross Atlantic Partners, which she joined in 2000. She is also currently President of NeuroNetworks Fund, a not-for-profit venture capital fund focusing on neurodisorders which she co-founded in December 2014. From 1994 to 1999 Dr. Panem was President of Vector Fund Management, the then asset management affiliate of Vector Securities International. Prior thereto, Dr. Panem served as Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a mutual fund that invested in public and private biotechnology companies. Previously, she was Vice President at Salomon Brothers Venture Capital, a fund focused on early and later-stage life sciences and technology investments. Dr. Panem was also a Science and Public Policy Fellow in economic studies at the Brookings Institution, and an Assistant Professor of Pathology at the University of Chicago. She received a B.S. in biochemistry and a Ph.D. in microbiology from the University of Chicago. Dr. Panem currently serves on the board of directors of BioLineRx Ltd. - Sandra Panem，女，博士，自1998年以来担任本公司董事会成员。她自2000年至今担任Cross Atlantic Partners的合伙人。1994到1999年，她担任Vector Fund Management（当时为 Vector Securities International的附属资产管理机构）的总裁。在此之前，她曾担任Oppenheimer Global BioTech Fund（投资于公共和私营生物科技企业的共同基金）的总裁兼投资部经理。此前，她曾担任Salomon Brothers Venture Capital（专注于早期和晚期阶段的生命科学和科技投资的基金）的副总裁。她也是布鲁金斯学会经济研究处的一名科学与公共政策研究员，并在芝加哥大学担任病理学助理教授。她持有芝加哥大学的生物化学理学士学位和芝加哥大学的微生物学博士学位。她目前担任Labcyte Inc、GenomeQuest Inc和MDx Medical Inc的董事会成员。
- Sandra Panem has been a member of our Board since 1998. She is currently a partner at Cross Atlantic Partners, which she joined in 2000. She is also currently President of NeuroNetworks Fund, a not-for-profit venture capital fund focusing on neurodisorders which she co-founded in December 2014. From 1994 to 1999 Dr. Panem was President of Vector Fund Management, the then asset management affiliate of Vector Securities International. Prior thereto, Dr. Panem served as Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a mutual fund that invested in public and private biotechnology companies. Previously, she was Vice President at Salomon Brothers Venture Capital, a fund focused on early and later-stage life sciences and technology investments. Dr. Panem was also a Science and Public Policy Fellow in economic studies at the Brookings Institution, and an Assistant Professor of Pathology at the University of Chicago. She received a B.S. in biochemistry and a Ph.D. in microbiology from the University of Chicago. Dr. Panem currently serves on the board of directors of BioLineRx Ltd.
- Lorin J. Randall
-
Lorin J. Randall自2007年9月担任董事。Randall先生是一名独立金融顾问，此前从2004年到2006年担任Eximias Pharmaceutical Corporation高级副总裁以及首席财务官，该公司是一家处于发展阶段的药物开发公司。从2002年到2004年，Randall先生担任i-STAT Corporation的高级副总裁和首席财务官，该公司是一家上市的医疗诊断设备生产商，该公司在2004年被Abbott Laboratories收购。从1995年到2001年，Randall先生是CFM Technologies, Inc的副总裁和首席财务官，该公司是一家上市的半导体制造设备的生产商。Randall先生目前任职于以下公司董事会，包括自2006年任职于Acorda Therapeutics, Inc.（纳斯达克（NASDAQ）代码： ACOR）董事会，他是审计委员会主席，同时也是薪酬以及提名和公司管理委员会成员；自2008年任职于Nanosphere, Inc.（纳斯达克（NASDAQ）代码： NSPH）董事会，他是审计委员会主席，同时也是薪酬委员会成员。他此前从2007年到2009年任职于Opexa Therapeutics, Inc.（纳斯达克（NASDAQ）代码：OPXA）董事会，他是该公司审计委员会主席。Randall先生从宾夕法尼亚州大学（Pennsylvania State University）获得会计学学士学位，从西北大学（Northeastern University）获得工商管理学硕士学位。
Lorin J. Randall has been a member of our Board since January 2006. Mr. Randall, a financial consultant, was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company, from 2004 to 2006. From 2002 to 2004 Mr. Randall served as Senior Vice President and Chief Financial Officer of i-STAT Corporation, a publicly-traded manufacturer of medical diagnostic devices that was acquired by Abbott Laboratories in 2004. From 1995 to 2001 Mr. Randall was Vice President and Chief Financial Officer of CFM Technologies, Inc., a publicly-traded manufacturer of semiconductor manufacturing equipment. He currently serves on the boards of directors of Athersys, Inc. where he serves as Chairperson of the Audit Committee, Chairperson of the Compensation Committee and member of the Nominations Committee. In addition, within the last five years, he previously served on the boards of directors of Aurinia Pharmaceuticals Inc., Nanosphere, Inc. and Tengion, Inc. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University. - Lorin J. Randall自2007年9月担任董事。Randall先生是一名独立金融顾问，此前从2004年到2006年担任Eximias Pharmaceutical Corporation高级副总裁以及首席财务官，该公司是一家处于发展阶段的药物开发公司。从2002年到2004年，Randall先生担任i-STAT Corporation的高级副总裁和首席财务官，该公司是一家上市的医疗诊断设备生产商，该公司在2004年被Abbott Laboratories收购。从1995年到2001年，Randall先生是CFM Technologies, Inc的副总裁和首席财务官，该公司是一家上市的半导体制造设备的生产商。Randall先生目前任职于以下公司董事会，包括自2006年任职于Acorda Therapeutics, Inc.（纳斯达克（NASDAQ）代码： ACOR）董事会，他是审计委员会主席，同时也是薪酬以及提名和公司管理委员会成员；自2008年任职于Nanosphere, Inc.（纳斯达克（NASDAQ）代码： NSPH）董事会，他是审计委员会主席，同时也是薪酬委员会成员。他此前从2007年到2009年任职于Opexa Therapeutics, Inc.（纳斯达克（NASDAQ）代码：OPXA）董事会，他是该公司审计委员会主席。Randall先生从宾夕法尼亚州大学（Pennsylvania State University）获得会计学学士学位，从西北大学（Northeastern University）获得工商管理学硕士学位。
- Lorin J. Randall has been a member of our Board since January 2006. Mr. Randall, a financial consultant, was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company, from 2004 to 2006. From 2002 to 2004 Mr. Randall served as Senior Vice President and Chief Financial Officer of i-STAT Corporation, a publicly-traded manufacturer of medical diagnostic devices that was acquired by Abbott Laboratories in 2004. From 1995 to 2001 Mr. Randall was Vice President and Chief Financial Officer of CFM Technologies, Inc., a publicly-traded manufacturer of semiconductor manufacturing equipment. He currently serves on the boards of directors of Athersys, Inc. where he serves as Chairperson of the Audit Committee, Chairperson of the Compensation Committee and member of the Nominations Committee. In addition, within the last five years, he previously served on the boards of directors of Aurinia Pharmaceuticals Inc., Nanosphere, Inc. and Tengion, Inc. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University.
- Steven M. Rauscher
-
Steven M. Rauscher自2005年3月起任职于本公司董事会。他是Euromedica（生命科学领域的猎头公司）的客户经理，并是BioPharm Physicians LLC（成立于2010年，为生物制药行业的医师和企业提供咨询服务）的创始人兼负责人。此前的2000年到2009年间，他曾担任Oscient Pharmaceuticals Corporation（商业化阶段的生物制药公司）的总裁兼首席执行官。他于2000年进入Oscient，且此前于1993年起担任董事会成员。此前，他在AmericasDoctor（向医药行业提供临床研究服务的公司）担任首席执行官。而更早前，他曾在Abbott Laboratories担任多个领导职务，包括公司副总裁、全球商务发展部副总裁、美国制药业务销售部副总裁。在最近5年里，他曾担任Oscient Pharmaceuticals Corporation的董事会成员。他持有印地安那大学的理学士学位和芝加哥大学的MBA学位。
Steven M. Rauscher has been a member of our Board since March 2005. He is Founder & Principal of BioPharm Physicians, LLC, a life sciences recruiting partnership formed in 2010 focusing on senior physician executives for biotech, pharmaceutical and medical device companies. Previously, he was President and Chief Executive Officer of Oscient Pharmaceuticals Corporation, a commercial stage biopharmaceutical company, from 2000 to 2009. He joined Oscient in 2000 having served as a member of the Board of Directors since 1993. Previously, Mr. Rauscher was Chief Executive Officer of AmericasDoctor, a company providing clinical research services to the pharmaceutical industry. Prior to AmericasDoctor, he held a number of leadership positions at Abbott Laboratories, including Vice President of Corporate Licensing, Vice President of Business Development, International Division and Vice President of Sales, U.S. Pharmaceuticals. Mr. Rauscher received a B.S. from Indiana University and an M.B.A. from the University of Chicago. - Steven M. Rauscher自2005年3月起任职于本公司董事会。他是Euromedica（生命科学领域的猎头公司）的客户经理，并是BioPharm Physicians LLC（成立于2010年，为生物制药行业的医师和企业提供咨询服务）的创始人兼负责人。此前的2000年到2009年间，他曾担任Oscient Pharmaceuticals Corporation（商业化阶段的生物制药公司）的总裁兼首席执行官。他于2000年进入Oscient，且此前于1993年起担任董事会成员。此前，他在AmericasDoctor（向医药行业提供临床研究服务的公司）担任首席执行官。而更早前，他曾在Abbott Laboratories担任多个领导职务，包括公司副总裁、全球商务发展部副总裁、美国制药业务销售部副总裁。在最近5年里，他曾担任Oscient Pharmaceuticals Corporation的董事会成员。他持有印地安那大学的理学士学位和芝加哥大学的MBA学位。
- Steven M. Rauscher has been a member of our Board since March 2005. He is Founder & Principal of BioPharm Physicians, LLC, a life sciences recruiting partnership formed in 2010 focusing on senior physician executives for biotech, pharmaceutical and medical device companies. Previously, he was President and Chief Executive Officer of Oscient Pharmaceuticals Corporation, a commercial stage biopharmaceutical company, from 2000 to 2009. He joined Oscient in 2000 having served as a member of the Board of Directors since 1993. Previously, Mr. Rauscher was Chief Executive Officer of AmericasDoctor, a company providing clinical research services to the pharmaceutical industry. Prior to AmericasDoctor, he held a number of leadership positions at Abbott Laboratories, including Vice President of Corporate Licensing, Vice President of Business Development, International Division and Vice President of Sales, U.S. Pharmaceuticals. Mr. Rauscher received a B.S. from Indiana University and an M.B.A. from the University of Chicago.
- Peder K. Jensen
-
Peder K. Jensen，医学博士，自2011年4月起担任本公司董事局成员。他目前担任Bay Way Consultants LLC的总裁，该公司是他于2010年所建的制药和生物技术咨询公司。他曾在Schering-Plough Corporation（跨国制药公司）任职达20多年，且在2009年Schering-Plough与Merck合并后，曾在Merck&Co.Inc任职。在 Schering-Plough/Merck的任职期间，他曾担任多个国际性高级研发岗位，包括：在SPRI临床研究部担任副总裁；在SPRI国际药物研发部担任执行副总裁；最近曾担任企业高级副总裁；2006至2010年间担任日本和亚太区研发部总经理。他在各治疗领域拥有24年多的全球药物研发经验，包括神经内科、心血管、抗感染，肿瘤学和免疫学。在他的职业生涯中，他曾负责全球40多种新药的批文，包括在美国、欧洲和日本区域。他目前还担任BioCryst Pharmaceuticals Inc和FivePrime Therapeutics Inc的董事会成员。他持有哥本哈根大学的医学博士学位。
Peder K. Jensen has been a member of our Board of Directors since April 2011. Dr. Jensen is currently president of Bay Way Consultants, LLC, a consulting firm founded by Dr. Jensen in 2010 that advises pharmaceutical and biotechnology companies. Dr. Jensen’s experience includes over 20 years with Schering-Plough Corporation, a global pharmaceutical company, and then Merck & Co., Inc. after the merger of Schering-Plough with Merck in 2009. During his tenure at Schering-Plough/Merck, Dr. Jensen held a number of global senior research and development positions, including Vice President Clinical Research, SPRI, Executive Vice President Worldwide Drug Development, SPRI, and most recently Corporate Senior Vice President, and General Manager, R&D for Japan and Asia/Pacific from 2006 to 2010. Dr. Jensen has more than 27 years of global drug development experience across a variety of therapeutic areas, including neurology, cardiovascular, anti-infective, oncology and immunology. Over the course of his career, Dr. Jensen has been responsible for more than 40 new drug approvals worldwide, including in the U.S., Europe and Japan. Dr. Jensen is currently a member of the board of directors of Five Prime Therapeutics, Inc., where he serves as Chairperson of the Compensation and Management Development Committee, a member of the Nominating and Corporate Governance Committee, and a member of the Research and Development Committee. Dr. Jensen previously was a member of the board of directors of BioCryst Pharmaceuticals, Inc. Dr. Jensen received his M.D. from the University of Copenhagen. - Peder K. Jensen，医学博士，自2011年4月起担任本公司董事局成员。他目前担任Bay Way Consultants LLC的总裁，该公司是他于2010年所建的制药和生物技术咨询公司。他曾在Schering-Plough Corporation（跨国制药公司）任职达20多年，且在2009年Schering-Plough与Merck合并后，曾在Merck&Co.Inc任职。在 Schering-Plough/Merck的任职期间，他曾担任多个国际性高级研发岗位，包括：在SPRI临床研究部担任副总裁；在SPRI国际药物研发部担任执行副总裁；最近曾担任企业高级副总裁；2006至2010年间担任日本和亚太区研发部总经理。他在各治疗领域拥有24年多的全球药物研发经验，包括神经内科、心血管、抗感染，肿瘤学和免疫学。在他的职业生涯中，他曾负责全球40多种新药的批文，包括在美国、欧洲和日本区域。他目前还担任BioCryst Pharmaceuticals Inc和FivePrime Therapeutics Inc的董事会成员。他持有哥本哈根大学的医学博士学位。
- Peder K. Jensen has been a member of our Board of Directors since April 2011. Dr. Jensen is currently president of Bay Way Consultants, LLC, a consulting firm founded by Dr. Jensen in 2010 that advises pharmaceutical and biotechnology companies. Dr. Jensen’s experience includes over 20 years with Schering-Plough Corporation, a global pharmaceutical company, and then Merck & Co., Inc. after the merger of Schering-Plough with Merck in 2009. During his tenure at Schering-Plough/Merck, Dr. Jensen held a number of global senior research and development positions, including Vice President Clinical Research, SPRI, Executive Vice President Worldwide Drug Development, SPRI, and most recently Corporate Senior Vice President, and General Manager, R&D for Japan and Asia/Pacific from 2006 to 2010. Dr. Jensen has more than 27 years of global drug development experience across a variety of therapeutic areas, including neurology, cardiovascular, anti-infective, oncology and immunology. Over the course of his career, Dr. Jensen has been responsible for more than 40 new drug approvals worldwide, including in the U.S., Europe and Japan. Dr. Jensen is currently a member of the board of directors of Five Prime Therapeutics, Inc., where he serves as Chairperson of the Compensation and Management Development Committee, a member of the Nominating and Corporate Governance Committee, and a member of the Research and Development Committee. Dr. Jensen previously was a member of the board of directors of BioCryst Pharmaceuticals, Inc. Dr. Jensen received his M.D. from the University of Copenhagen.
高管简历
中英对照 | 中文 | 英文- Burkhard Blank
Burkhard Blank自2016年7月起担任我们的首席医疗官，并于2019年3月被任命为我们的研发主管。在此之前，Blank博士于2016年1月至2016年6月受聘于公司，以临时承担首席医疗官职责。Blank博士在制药行业拥有超过28年的经验。任职公司之前，Blank博士于2014年6月至2016年6月担任Herantis Pharma的首席医疗官。从2013年6月到2014年5月，他曾担任Laurantis Pharma公司的首席执行官，也曾担任咨询首席医疗官（从2012年6月到2013年5月）。在此之前，Blank从2010年10月到2012年6月担任Mersana Therapeutics咨询首席医疗官。Blank博士此前曾担任首席医疗官，并在几家生物制药公司担任各种医疗领导职务，包括Inhibikase Pharmaceuticals，Qwell Pharmaceuticals，New Haven Pharmaceuticals，Alnara Pharmaceuticals和Boehringer Ingelheim BI。任职BI公司期间，他曾监管5个新药申请（NDA）的提交，并直接负责在两次FDA咨询委员会会议上提交的所有方面；随后，所有5个NDA都获得FDA批准。Blank博士还曾担任多家生物技术公司的战略顾问，领导多个研究性药物申请（INDS）的提交过程，成功开发临床试验计划的协议，并监督与监管机构的沟通。Blank博士此前曾在Riemser Pharma GmbH的董事会任职。Blank博士在德国马尔堡大学（Universitaet Marburg）获得医学学位。他在德国获得内科的董事会认证。
Burkhard Blank has been our Chief Medical Officer since July 2016 and in March 2019 he was also appointed as our Head of R&D. Prior to that, from January 2016 to June 2016 Dr. Blank was engaged by the Company to assume chief medical officer responsibilities on an interim basis. Dr. Blank has more than 28 years of experience in the pharmaceutical industry. Prior to working for the Company, from June 2014 to June 2016 Dr. Blank was the Chief Medical Officer of Herantis Pharma. From June 2013 to May 2014 he was the Chief Executive Officer of Laurantis Pharma and from June 2012 to May 2013 Dr. Blank acted as a consulting chief medical officer. Prior thereto, from October 2010 to June 2012 Dr. Blank served as a consulting chief medical officer for Mersana Therapeutics. Dr. Blank previously consulted as chief medical officer and served in various medical leadership roles for several biopharmaceutical companies, including Inhibikase Pharmaceuticals, Qwell Pharmaceuticals, New Haven Pharmaceuticals, Alnara Pharmaceuticals, Altus Pharmaceuticals, and Boehringer Ingelheim BI. While at BI, he oversaw the submission of five New Drug Applications (NDAs) and had direct responsibility for all aspects of presenting at two FDA Advisory Committee Meetings; and subsequently, all five NDAs received FDA approval. Dr. Blank has also served as a strategic advisor to several biotechnology companies, leading the submission process for multiple Investigational Drug Applications (INDs), successfully developing protocols for clinical trial programs, and overseeing communications with regulatory agencies. Dr. Blank previously served on the Board of Directors of Riemser Pharma GmbH. Dr. Blank received his medical degree from Universitaet Marburg, Germany. He is board-certified in Germany in internal medicine.- Burkhard Blank自2016年7月起担任我们的首席医疗官，并于2019年3月被任命为我们的研发主管。在此之前，Blank博士于2016年1月至2016年6月受聘于公司，以临时承担首席医疗官职责。Blank博士在制药行业拥有超过28年的经验。任职公司之前，Blank博士于2014年6月至2016年6月担任Herantis Pharma的首席医疗官。从2013年6月到2014年5月，他曾担任Laurantis Pharma公司的首席执行官，也曾担任咨询首席医疗官（从2012年6月到2013年5月）。在此之前，Blank从2010年10月到2012年6月担任Mersana Therapeutics咨询首席医疗官。Blank博士此前曾担任首席医疗官，并在几家生物制药公司担任各种医疗领导职务，包括Inhibikase Pharmaceuticals，Qwell Pharmaceuticals，New Haven Pharmaceuticals，Alnara Pharmaceuticals和Boehringer Ingelheim BI。任职BI公司期间，他曾监管5个新药申请（NDA）的提交，并直接负责在两次FDA咨询委员会会议上提交的所有方面；随后，所有5个NDA都获得FDA批准。Blank博士还曾担任多家生物技术公司的战略顾问，领导多个研究性药物申请（INDS）的提交过程，成功开发临床试验计划的协议，并监督与监管机构的沟通。Blank博士此前曾在Riemser Pharma GmbH的董事会任职。Blank博士在德国马尔堡大学（Universitaet Marburg）获得医学学位。他在德国获得内科的董事会认证。
- Burkhard Blank has been our Chief Medical Officer since July 2016 and in March 2019 he was also appointed as our Head of R&D. Prior to that, from January 2016 to June 2016 Dr. Blank was engaged by the Company to assume chief medical officer responsibilities on an interim basis. Dr. Blank has more than 28 years of experience in the pharmaceutical industry. Prior to working for the Company, from June 2014 to June 2016 Dr. Blank was the Chief Medical Officer of Herantis Pharma. From June 2013 to May 2014 he was the Chief Executive Officer of Laurantis Pharma and from June 2012 to May 2013 Dr. Blank acted as a consulting chief medical officer. Prior thereto, from October 2010 to June 2012 Dr. Blank served as a consulting chief medical officer for Mersana Therapeutics. Dr. Blank previously consulted as chief medical officer and served in various medical leadership roles for several biopharmaceutical companies, including Inhibikase Pharmaceuticals, Qwell Pharmaceuticals, New Haven Pharmaceuticals, Alnara Pharmaceuticals, Altus Pharmaceuticals, and Boehringer Ingelheim BI. While at BI, he oversaw the submission of five New Drug Applications (NDAs) and had direct responsibility for all aspects of presenting at two FDA Advisory Committee Meetings; and subsequently, all five NDAs received FDA approval. Dr. Blank has also served as a strategic advisor to several biotechnology companies, leading the submission process for multiple Investigational Drug Applications (INDs), successfully developing protocols for clinical trial programs, and overseeing communications with regulatory agencies. Dr. Blank previously served on the Board of Directors of Riemser Pharma GmbH. Dr. Blank received his medical degree from Universitaet Marburg, Germany. He is board-certified in Germany in internal medicine.
- Ron Cohen
Ron Cohen，医学博士，担任本公司总裁、首席执行官兼创始人。他曾参与Advanced Tissue Sciences Inc的创办，而该公司是一家生物技术公司，从事人体器官组织的培植和移植。他在普林斯顿大学获得心理学文学士学位，在哥伦比亚大学获得内外科医学博士学位。他在弗吉尼亚大学医学中心完成内科专业的实习，并获得认证。他目前担任 Dyax Corp的董事会成员。他曾担任纽约生物技术协会的董事兼董事会主席。他目前是生物技术工业组织（BIO）的执行委员会成员，并任其卫生科副科长。他还是哥伦比亚长老会医疗科学顾问委员会的成员，并荣获哥伦比亚大学卓越校友奖。2010年，他被任命为NeuroInvestment（现为NeuroPerspective）的年度执行总裁，且于2009年被PharmaVoice杂志评为生物医药产业百佳卓越人士。他是纽约大都会地区的安永企业家奖的获得者，且被列入全国脊髓损伤协会主办的“脊髓损伤大厅名人堂”。2010年，他被纽约生物技术协会评为NYBA“The Cure Starts Here”的年度商业领袖。
Ron Cohen has served as Dyax Corp. President and Chief Executive Officer since he founded the Company in 1995. Dr. Cohen previously was a principal in the startup of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen currently serves on the board of directors of VBL Therapeutics. In addition, within the last five years, he previously served on the board of directors of Dyax Corp. Dr. Cohen previously served as Chair of the board of the Biotechnology Innovation Organization BIO, as Chair of the Emerging Companies Section of the BIO board, and as a Director and Chairman of New York Biotechnology Association (NYBA). He also previously served as a member of the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University's Alumni Medal for Distinguished Service. In 2010 Dr. Cohen was named NeuroInvestment's (now called NeuroPerspective) CEO of the Year and in 2009 he was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. Dr. Cohen is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and is an inductee into the National Spinal Cord Injury Association's "Spinal Cord Injury Hall of Fame." In 2010 Dr. Cohen was recognized by NYBA as its "The Cure Starts Here" Business Leader of the Year and was named by MM&M and PR Week as one of the top 50 health influencers of 2017.- Ron Cohen，医学博士，担任本公司总裁、首席执行官兼创始人。他曾参与Advanced Tissue Sciences Inc的创办，而该公司是一家生物技术公司，从事人体器官组织的培植和移植。他在普林斯顿大学获得心理学文学士学位，在哥伦比亚大学获得内外科医学博士学位。他在弗吉尼亚大学医学中心完成内科专业的实习，并获得认证。他目前担任 Dyax Corp的董事会成员。他曾担任纽约生物技术协会的董事兼董事会主席。他目前是生物技术工业组织（BIO）的执行委员会成员，并任其卫生科副科长。他还是哥伦比亚长老会医疗科学顾问委员会的成员，并荣获哥伦比亚大学卓越校友奖。2010年，他被任命为NeuroInvestment（现为NeuroPerspective）的年度执行总裁，且于2009年被PharmaVoice杂志评为生物医药产业百佳卓越人士。他是纽约大都会地区的安永企业家奖的获得者，且被列入全国脊髓损伤协会主办的“脊髓损伤大厅名人堂”。2010年，他被纽约生物技术协会评为NYBA“The Cure Starts Here”的年度商业领袖。
- Ron Cohen has served as Dyax Corp. President and Chief Executive Officer since he founded the Company in 1995. Dr. Cohen previously was a principal in the startup of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen currently serves on the board of directors of VBL Therapeutics. In addition, within the last five years, he previously served on the board of directors of Dyax Corp. Dr. Cohen previously served as Chair of the board of the Biotechnology Innovation Organization BIO, as Chair of the Emerging Companies Section of the BIO board, and as a Director and Chairman of New York Biotechnology Association (NYBA). He also previously served as a member of the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University's Alumni Medal for Distinguished Service. In 2010 Dr. Cohen was named NeuroInvestment's (now called NeuroPerspective) CEO of the Year and in 2009 he was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. Dr. Cohen is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and is an inductee into the National Spinal Cord Injury Association's "Spinal Cord Injury Hall of Fame." In 2010 Dr. Cohen was recognized by NYBA as its "The Cure Starts Here" Business Leader of the Year and was named by MM&M and PR Week as one of the top 50 health influencers of 2017.
- David Lawrence
David Lawrence，自2013年10月以来担任本公司业务营运部总裁，且曾在2005年1月开始担任本公司财务总监。2001年1月至2004年，他曾担任本公司财务部副总裁，且在1999至2001年就已担任财务部主管。1991至1999年，他曾在Tel-Air Communications, Inc担任多项职务，包括副总裁兼财务主管。而加入Tel-Air之前，他曾分别在Southwestern Bell和Metromedia Telecommunications担任财务主管和财务经理。他在罗·威廉斯学院获得会计学学士学位，并于爱纳大学获得财务学MBA学位。他是 Brian Ahearn Children's Fund的创始人之一，目前担任其董事会成员间财务总监。
David Lawrence has been our Chief, Business Operations and Principal Accounting Officer since October 2016. Prior to that, he served as Chief of Business Operations from October 2013 to October 2016. From January 2005 to October 2013 he served as our Chief Financial Officer. He previously served as our Vice President, Finance from January 2001 through 2004 and Director, Finance from 1999 to 2001. From 1991 to 1999 Mr. Lawrence held several positions for Tel-Air Communications, Inc., including Vice President and Controller. Prior to Tel-Air, he held the financial management positions of Controller and Finance Manager for Southwestern Bell and Metromedia Telecommunications, respectively. Mr. Lawrence received his undergraduate degree in Accounting from Roger Williams College, and an M.B.A. in Finance from Iona College. Mr. Lawrence is a founding member and currently serves on the board of directors and as Treasurer of The Brian Ahearn Children’s Fund.- David Lawrence，自2013年10月以来担任本公司业务营运部总裁，且曾在2005年1月开始担任本公司财务总监。2001年1月至2004年，他曾担任本公司财务部副总裁，且在1999至2001年就已担任财务部主管。1991至1999年，他曾在Tel-Air Communications, Inc担任多项职务，包括副总裁兼财务主管。而加入Tel-Air之前，他曾分别在Southwestern Bell和Metromedia Telecommunications担任财务主管和财务经理。他在罗·威廉斯学院获得会计学学士学位，并于爱纳大学获得财务学MBA学位。他是 Brian Ahearn Children's Fund的创始人之一，目前担任其董事会成员间财务总监。
- David Lawrence has been our Chief, Business Operations and Principal Accounting Officer since October 2016. Prior to that, he served as Chief of Business Operations from October 2013 to October 2016. From January 2005 to October 2013 he served as our Chief Financial Officer. He previously served as our Vice President, Finance from January 2001 through 2004 and Director, Finance from 1999 to 2001. From 1991 to 1999 Mr. Lawrence held several positions for Tel-Air Communications, Inc., including Vice President and Controller. Prior to Tel-Air, he held the financial management positions of Controller and Finance Manager for Southwestern Bell and Metromedia Telecommunications, respectively. Mr. Lawrence received his undergraduate degree in Accounting from Roger Williams College, and an M.B.A. in Finance from Iona College. Mr. Lawrence is a founding member and currently serves on the board of directors and as Treasurer of The Brian Ahearn Children’s Fund.
- Lauren M. Sabella
Lauren M. Sabella自2010年1月起担任本公司商务发展部执行副总裁。她是Tugboat Consulting Group（一家独立管理咨询实践企业）的创始人兼负责人。2006年5月至2008年9月，她还担任Altus Pharmaceuticals的商务发展部企业主管兼副总裁，负责商务业务。在进入Altus之前，她曾在 Boehringer Ingelheim Pharmaceuticals任职长达18年，且最后再该公司任东部地区销售部副总裁，成功推行了Spiriva并带领基础护理和特殊护理分部，包括神经内科、泌尿科和心肺科。在此之前，她有10多年的市场营销经验，推出过多个品牌，其中包括Mobic（后来成为市值10亿美元的NSAID 品牌）。她持有霍夫斯特拉大学的BBA学位。
Lauren M. Sabella has been our Chief Commercial Officer since February 2015. Prior to that, from January 2010 to February 2015 she was our Executive Vice President, Commercial Development. Ms. Sabella was the Founder and Principal of Tugboat Consulting Group, an independent consulting practice assisting companies in the commercialization process. Ms. Sabella also served as Corporate Officer and VP of Commercial Development at Altus Pharmaceuticals from May 2006 to September 2008 with responsibility for all aspects of commercialization. Prior to joining Altus, Ms. Sabella was employed by Boehringer Ingelheim Pharmaceuticals for 18 years in positions of increasing responsibility. In her last role, she served as VP of Sales, Eastern Zone, where she led the successful sales launch of Spiriva and ran both Primary Care and Specialty Divisions, including Neurology, Urology and Cardio/Pulmonary. Prior to this role, she had over ten years of marketing experience where she led several product launches including Mobic, an NSAID which became a $1 billion brand. Ms. Sabella holds a B.B.A. from Hofstra University.- Lauren M. Sabella自2010年1月起担任本公司商务发展部执行副总裁。她是Tugboat Consulting Group（一家独立管理咨询实践企业）的创始人兼负责人。2006年5月至2008年9月，她还担任Altus Pharmaceuticals的商务发展部企业主管兼副总裁，负责商务业务。在进入Altus之前，她曾在 Boehringer Ingelheim Pharmaceuticals任职长达18年，且最后再该公司任东部地区销售部副总裁，成功推行了Spiriva并带领基础护理和特殊护理分部，包括神经内科、泌尿科和心肺科。在此之前，她有10多年的市场营销经验，推出过多个品牌，其中包括Mobic（后来成为市值10亿美元的NSAID 品牌）。她持有霍夫斯特拉大学的BBA学位。
- Lauren M. Sabella has been our Chief Commercial Officer since February 2015. Prior to that, from January 2010 to February 2015 she was our Executive Vice President, Commercial Development. Ms. Sabella was the Founder and Principal of Tugboat Consulting Group, an independent consulting practice assisting companies in the commercialization process. Ms. Sabella also served as Corporate Officer and VP of Commercial Development at Altus Pharmaceuticals from May 2006 to September 2008 with responsibility for all aspects of commercialization. Prior to joining Altus, Ms. Sabella was employed by Boehringer Ingelheim Pharmaceuticals for 18 years in positions of increasing responsibility. In her last role, she served as VP of Sales, Eastern Zone, where she led the successful sales launch of Spiriva and ran both Primary Care and Specialty Divisions, including Neurology, Urology and Cardio/Pulmonary. Prior to this role, she had over ten years of marketing experience where she led several product launches including Mobic, an NSAID which became a $1 billion brand. Ms. Sabella holds a B.B.A. from Hofstra University.